AGILE THERAPEUTICS INC
AGRX evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Lead Asset:
- twirla (Approved)
What it means
What to watch
Prepared research question
What matters most for AGRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 1 pipeline candidate · 1 clinical trial · 1 FDA decision for AGILE THERAPEUTICS INC.
Run AGILE THERAPEUTICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AGILE THERAPEUTICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is AGILE THERAPEUTICS INC's lead drug candidate?
AGILE THERAPEUTICS INC's most advanced tracked candidate is twirla (Approved) for contraception for use in women of reproductive potential with a body mass index ("BMI") < 30 kg/m2.
What therapeutic areas does AGILE THERAPEUTICS INC focus on?
AGILE THERAPEUTICS INC develops therapies across Oncology, Respiratory, Dermatology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.